Core Viewpoint - The announcement from XinNuoWei indicates that its subsidiary, Jushi Biopharma, has achieved top-line analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] Group 1: Product Development - Secukinumab is developed as a biosimilar to Cosentyx, which has been approved in China for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1] Group 2: Market Context - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients suffering from psoriasis in China [1] - Interleukin (IL)-17A, primarily produced by activated T cells, is a key molecule in the pathogenesis of psoriasis [1] Group 3: Mechanism of Action - Secukinumab specifically binds to IL-17A, blocking the signaling of the IL-17 receptor, thereby inhibiting the inflammation associated with psoriasis [1]

证券代码：300765 证券简称：新诺威 公告编号：2025-097 石药创新制药股份有限公司 关于控股子公司司库奇尤单抗注射液 III 期临床试验 获得顶线分析数据的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）开发的司库奇尤单抗注射液（以下 简称"该产品"）于近日在 III 期临床试验中获得顶线分析数据。现将相关情况 公告如下： 一、药品的基本信息 1 该项关键研究已达到预设主要终点，并取得积极的顶线结果，统计分析表明， 该产品与可善挺®具有临床等效性，且安全性良好，未出现新的或非预期的安全 性信号，有望能满足患者长期用药的安全性需求。有关详细数据将于后续学术会 议及期刊上发布。 三、风险提示 1、根据国家药品注册相关的法律法规要求，药品需通过国家药监局相关审 评程序并获批准后方可上市、销售。 2、药品研发有着高投入、高风险、周期长等特点。存在未能通过相关主管 部门的审批、上市时间晚于计划时间或上市后销量未及预期等风险。短期对巨石 生物及公 ...

Group 1 - The core viewpoint of the news highlights the performance of the ChiNext ETF Tianhong (159977), which has seen significant capital inflow despite a decline in the ChiNext Index (399006) by 1.78% [1][2] - As of December 18, 2025, the trading volume of the ChiNext ETF Tianhong reached 161 million yuan, with a notable subscription of 40 million shares [1][2] - The ETF has experienced a growth of 1.26 billion yuan in the past week and an increase of 10.62 billion shares over the last six months, indicating strong demand [2] Group 2 - The ChiNext ETF Tianhong tracks a diverse index that includes high-growth sectors such as pharmaceuticals, new energy, computing power, and brokerage, which are expected to benefit from trends like innovation in pharmaceuticals and strong demand for AI computing power [2] - The current Price-to-Earnings (PE) ratio of the index is 40.51, which is in the relatively undervalued zone at the 33.79% historical percentile since its inception, suggesting attractive investment value [2] - The launch of humanoid robots in CATL's battery production line marks a significant milestone in the application of embodied intelligence in smart manufacturing [4] Group 3 - Institutional views suggest that the market is currently in a high-level consolidation phase, with expectations for a structural bull market in 2026, favoring cyclical and value styles in the first half of the year [4][5] - The economic environment for 2026 is expected to be more balanced and stable, supporting a positive trend in the equity market [5]

Core Viewpoint - The food and beverage ETF Tianhong (159736) and the agriculture ETF Tianhong (512620) are experiencing significant capital inflows, indicating investor interest in these sectors amid a mixed performance of underlying stocks [1][2][3]. Food and Beverage Sector - As of December 18, 2025, the food and beverage ETF Tianhong (159736) recorded a transaction volume of 13.79 million yuan, with the underlying index showing an upward trend and achieving four consecutive days of gains [1]. - The top-performing stocks within the food and beverage ETF include Laiyifen (603777) with a 10.01% increase, Xinnuowei (300765) up by 8.10%, and Liangpinpuzi (603719) rising by 4.48% [1]. - Over the past 10 trading days, the food and beverage ETF has attracted a total of 42.82 million yuan in capital [2]. - The ETF's portfolio is heavily weighted towards leading high-end and mid-range liquor stocks, with approximately 60% of its holdings in this category, while the remaining 40% includes leaders in beverages, dairy, condiments, and beer [4]. Agriculture Sector - The agriculture ETF Tianhong (512620) has seen a significant increase in scale, with a growth of 55.54 million yuan over the past week and an increase of 50 million shares [3]. - The agriculture ETF has also experienced continuous net inflows over the last four days, with a peak single-day net inflow of 30.62 million yuan, totaling 49.41 million yuan in capital [3]. - The agriculture ETF tracks the China Securities Agricultural Index, selecting 50 stocks that cover various sectors, including breeding (41.9%) and agricultural chemicals (17.7%), featuring leading companies like Muyuan and Haida [4]. Regulatory and Market Environment - The State Council's Food Safety Office has emphasized the importance of food safety management in preparation for the upcoming New Year, Spring Festival, and national meetings, aiming to ensure a safe environment for the public [7]. - China's agricultural seed autonomy has surpassed 95%, with significant achievements in domestic seed variety development, indicating a strong foundation for agricultural security [8]. - According to Zhongjin Company, the food and beverage industry is entering a new normal, with a weak overall consumption environment and a trend towards high quality-price ratios, functional products, and health-oriented consumption [9].

Core Viewpoint - The innovation drug sector is experiencing a phase of risk clearance, with significant stock price increases observed in both A-shares and Hong Kong stocks, indicating a positive market sentiment towards the sector [1]. Group 1: Market Performance - Chinese health stocks, such as Huaren Health, have seen a 20% surge, while companies like Saili Medical and Zhongyao Holdings have also reached their daily price limits [1]. - The Hong Kong Stock Connect innovation drug ETF has recorded net inflows for seven consecutive days, with the latest fund share reaching 4.172 billion, marking a new high since its listing [1]. Group 2: Legislative Impact - The revised U.S. Biodefense Act, part of the 2026 National Defense Authorization Act (NDAA), was passed with 77 votes in favor and 20 against, and will soon be sent to the White House for presidential approval [1]. - The new version of the Biodefense Act does not specifically name any companies but mandates the White House Office of Management and Budget to create a list of restricted companies within a year based on relevant Department of Defense lists [1]. Group 3: Industry Outlook - Analysts suggest that the 2025 legislative developments will lead to a return to long-term growth logic for the industry, with a focus on the competitive advantages of leading companies in the CXO sector [2]. - The CXO sector is expected to see improved valuation and sustained upward trends in business operations, driven by external factors such as the U.S. Biodefense Act and domestic economic recovery [2][3]. - The overall demand for CXO services is showing a positive trend, with both order volumes and financing activities indicating a favorable outlook for the sector [3].

Core Viewpoint - The recent passing of the revised Biological Safety Act as part of the U.S. National Defense Authorization Act (NDAA) for fiscal year 2026 is expected to positively impact the innovative drug sector, leading to a recovery in stock prices and a return to long-term growth logic for the industry [1][2]. Group 1: Market Reaction - A-shares and Hong Kong stocks in the innovative drug sector saw significant gains, with companies like Huaren Health and Saily Medical reaching their daily limit up [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced net inflows for seven consecutive days, with its fund size reaching a record high of 4.172 billion shares [1]. Group 2: Legislative Impact - The revised Biological Safety Act was passed with a vote of 77 in favor and 20 against, and it will be managed by the Office of Management and Budget (OMB) to create a list of restricted companies within a year [2]. - Analysts believe that the passage of the act marks a significant milestone for the industry, allowing for a return to a long-term growth perspective [2]. Group 3: Industry Outlook - The CXO sector has shown improved valuation attractiveness following adjustments in Q4 2025, with expectations for continued upward trends in 2026 [3]. - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing signs of marginal improvement, leading to a more favorable sentiment [4]. - The overall demand for CXO services is on the rise, with both order volumes and financing showing positive trends [4]. Group 4: Strategic Partnerships - Recent collaborations, such as the agreement between Senrida Medical and Boston Scientific, indicate increased interest from leading global pharmaceutical companies in Chinese innovative medical devices [5]. - The medical device sector is positioned to benefit from advancements in medical information technology and AI applications, enhancing productivity [5].

Group 1 - The core viewpoint of the article highlights a significant rebound in the innovative drug sector in both A-shares and Hong Kong stocks, with notable stocks like Huaren Health and Seli Medical reaching their daily limit up [2] - The approval of the revised Biological Safety Act as part of the U.S. National Defense Authorization Act for fiscal year 2026 is expected to positively impact the industry, with the act not specifically naming any companies but indicating future management of restricted enterprises [3] - Analysts suggest that the passage of the 2025 legislation marks a phase of stabilization for the industry, allowing a return to long-term growth logic, particularly for leading companies like WuXi AppTec, which have shown strong performance despite previous market fluctuations [3][4] Group 2 - The CXO sector has seen improved valuation attractiveness following adjustments in Q4 2025, with expectations of continued upward trends in industry operations for 2026 [4] - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing marginal improvement, leading to a more favorable sentiment and the beginning of a new high prosperity cycle driven by overseas interest rate cuts and domestic recovery [6] - The overall demand for CXO services is on the rise, with both order volumes and financing showing positive trends, indicating a robust recovery in the sector [6]

Core Viewpoint - The recent approval of the revised Biological Safety Act as part of the 2026 National Defense Authorization Act (NDAA) in the U.S. is expected to positively impact the innovative drug sector, leading to a recovery in the industry and a return to long-term growth logic [2][4]. Group 1: Market Performance - A-shares and Hong Kong stocks in the innovative drug sector have seen significant gains, with companies like Huaren Health and Seli Medical hitting the daily limit up of 20% [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced a net inflow of funds for seven consecutive days, with the latest fund size reaching 4.172 billion shares, a record high since its listing [1]. Group 2: Legislative Impact - The revised Biological Safety Act was passed with a vote of 77 to 20 and will be sent to the White House for presidential approval, which will make it effective immediately [2]. - The act does not specifically name any companies but mandates the Office of Management and Budget (OMB) to create a list of restricted companies within a year, based on input from the Department of Defense [2]. Group 3: Industry Outlook - Analysts believe that the passage of the 2025 NDAA marks a phase of stabilization for the industry, allowing for a focus on long-term growth opportunities [2]. - The CXO (Contract Research Organization) sector is showing improved valuation and is expected to experience upward trends in 2026, with leading companies maintaining competitive advantages [3][4]. Group 4: Economic Environment - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing signs of marginal improvement, leading to a more favorable sentiment in the market [4]. - The industry is entering a new high prosperity cycle driven by overseas interest rate cuts, domestic recovery, and industrial upgrades [4]. Group 5: Collaboration and Innovation - Recent collaborations, such as the agreement between Senrida Medical and Boston Scientific, indicate increased attention from global pharmaceutical companies towards innovative medical devices in China [5]. - The medical device sector is positioned to benefit from advancements in medical information technology and AI applications, enhancing productivity [5].

石药集团(01093)早盘涨近5%，截至发稿，涨4.79%，报7.88港元，成交额3.96亿港元。 消息面上，12月10日，石药创新首次向港交所递交招股书，拟在香港主板上市。公开资料显示，石药创 新由石药集团分拆而来，已于2019年3月在A股上市，A股简称为新诺威（300765）。若此次港股上市成 功，石药创新将成为又一家"A+H"两地上市的医药企业。 公开资料显示，2023年，石药创新完成企业名称变更，由新诺威正式更名为石药创新。次年又掏出 18.71亿元以增资方式完成对其"兄弟公司"巨石生物51%股权的收购，成为该公司的控股股东，正式将业 务链实质性延伸至生物创新药领域。此次石药创新赴港上市旨在通过外部融资减缓资金压力，支撑创新 药业务发展。 ...

公开资料显示，2023年，石药创新完成企业名称变更，由新诺威正式更名为石药创新。次年又掏出 18.71亿元以增资方式完成对其"兄弟公司"巨石生物51%股权的收购，成为该公司的控股股东，正式将业 务链实质性延伸至生物创新药领域。此次石药创新赴港上市旨在通过外部融资减缓资金压力，支撑创新 药业务发展。 消息面上，12月10日，石药创新首次向港交所递交招股书，拟在香港主板上市。公开资料显示，石药创 新由石药集团分拆而来，已于2019年3月在A股上市，A股简称为新诺威。若此次港股上市成功，石药创 新将成为又一家"A+H"两地上市的医药企业。 智通财经APP获悉，石药集团(01093)早盘涨近5%，截至发稿，涨4.79%，报7.88港元，成交额3.96亿港 元。 ...